0001127602-24-017764.txt : 20240604
0001127602-24-017764.hdr.sgml : 20240604
20240604172724
ACCESSION NUMBER: 0001127602-24-017764
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240531
FILED AS OF DATE: 20240604
DATE AS OF CHANGE: 20240604
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mock James M
CENTRAL INDEX KEY: 0001736359
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 241019611
MAIL ADDRESS:
STREET 1: 940 WINTER STREET
STREET 2: PERKINELMER
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 325 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 325 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-05-31
0001682852
Moderna, Inc.
MRNA
0001736359
Mock James M
325 BINNEY STREET
CAMBRIDGE
MA
02142
1
Chief Financial Officer
1
Common Stock
2024-05-31
4
M
0
1326
A
7197
D
Common Stock
2024-06-03
4
S
0
691
140.7198
D
6506
D
Performance Stock Units
2024-05-31
4
A
0
5304
0
A
Common Stock
5304
5304
D
Performance Stock Units
2024-05-31
4
M
0
1326
0
D
Common Stock
1326
3978
D
Performance stock units convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person.
25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025.
/s/ James Dillon, As Attorney-in-Fact
2024-06-04